Anti-IL-17 mAbs herald new options in psoriasis

Garber, Ken
June 2012
Nature Biotechnology;Jun2012, Vol. 30 Issue 6, p475
Academic Journal
The article presents information on Brodalumab, a monoclonal antibody (mAbs) developed by AstraZeneca in London and Amgen Inc. in Thousand Oaks, California that target interleukin-17 (IL-17) receptor. It has a spectacular efficacy towards psoriasis. A focus is on another antibody named ixekizumab which directly targets interleukin cytokine and on the treatment approaches. The techniques avoid the hitting of interleukin-12 so as to limit side effects and for preserving T-helper 1 immunity.


Related Articles

  • Centocor's Ustekinumab Bests Enbrel in Phase III Psoriasis Trial.  // BioWorld Today;9/19/2008, Vol. 19 Issue 183, p2 

    The article reports that Centocor's monoclonal antibody ustekinumab has demonstrated superior efficacy to Amgen's Enbrel in a Phase III psoriasis trial. Results of the ACCEPT trial revealed that more patients treated with ustekinumab achieved at least 75% reduction in psoriasis. Data presented...

  • Psoriasis treatment inhibits T-cell activation. Pearsall, Kathy // Dermatology Times;Jul2000, Vol. 21 Issue 7, p17 

    Reports on preliminary findings showing the efficacy of monoclonal antibody IDEC-114 in treating psoriasis. Inhibition of T-cell activation by blocking the interaction of CD80 and CD28 on the T-cell surface; Absence of infusion-related cytokine release symptoms.

  • Anti�Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis. Leonardi, Craig; Matheson, Robert; Zachariae, Claus; Cameron, Gregory; Li, Linda; Edson-Heredia, Emily; Braun, Daniel; Banerjee, Subhashis // New England Journal of Medicine;3/29/2012, Vol. 366 Issue 13, p1190 

    Background: Type 17 helper T cells have been suggested to play a pathological role in psoriasis. They secrete several proinflammatory cytokines, including interleukin-17A (also known as interleukin-17). We evaluated the safety and efficacy of ixekizumab (LY2439821), a humanized...

  • Pathological Role of Interleukin-17 in Poly I:C-Induced Hepatitis. He, Jianqin; Lang, Guanjing; Ding, Shiping; Li, Lanjuan // PLoS ONE;Sep2013, Vol. 8 Issue 9, p1 

    Immune-mediated responses were the main causes of liver damage during viral hepatitis, and recently viral RNA mimetic Poly I:C was used to induce a NK cell-dominated acute hepatitis. Interleukin-17A (IL-17A), the cytokine tightly associated with various autoimmune diseases, was known to play...

  • Interleukin-17 Retinotoxicity Is Prevented by Gene Transfer of a Soluble Interleukin-17 Receptor Acting as a Cytokine Blocker: Implications for Age-Related Macular Degeneration. Ardeljan, Daniel; Wang, Yujuan; Park, Stanley; Shen, Defen; Chu, Xi Kathy; Yu, Cheng-Rong; Abu-Asab, Mones; Tuo, Jingsheng; Eberhart, Charles G.; Olsen, Timothy W.; Mullins, Robert F.; White, Gary; Wadsworth, Sam; Scaria, Abraham; Chan, Chi-Chao // PLoS ONE;Apr2014, Vol. 9 Issue 4, p1 

    Age-related macular degeneration (AMD) is a common yet complex retinal degeneration that causes irreversible central blindness in the elderly. Pathology is widely believed to follow loss of retinal pigment epithelium (RPE) and photoreceptor degeneration. Here we report aberrant expression of...

  • IDEC-114 testing shows blocking of T-cell activation. Guttman, Cheryl // Dermatology Times;Nov99 Supplement 6, Vol. 20 Issue 11, pS24 

    Reports on the launch of a Phase I/II clinical trial investigating the safety, tolerability, and pharmacokinetics of IDEC-114, an anti-B7-1 monoclonal antibody for the treatment of psoriasis. Administration of multiple drug doses that may provide an insight into clinical activity of IDEC-114;...

  • Genetically predetermined limitation in HaCaT cells that affects their ability to serve as an experimental model of psoriasis. Soboleva, A.; Zolotarenko, A.; Sobolev, V.; Bruskin, S.; Piruzian, E.; Mezentsev, A. // Russian Journal of Genetics;Oct2014, Vol. 50 Issue 10, p1081 

    Proinflammatory cytokines TNF, IFNG, and IL17 play an important role in eruption of psoriasis. The activation of epidermal keratinocytes with the named cytokines alters their terminal differentiation program and causes their hyperproliferation in the diseased skin. HaCaT cells, which are...

  • Innate immune cells express IL-17A/F in acute generalized exanthematous pustulosis and generalized pustular psoriasis. Kakeda, M.; Schlapbach, Christoph; Danelon, G.; Tang, M.; Cecchinato, V.; Yawalkar, N.; Uguccioni, M. // Archives of Dermatological Research;Dec2014, Vol. 306 Issue 10, p933 

    Acute generalized exanthematous pustulosis (AGEP) and generalized pustular psoriasis (GPP) are rare pustular skin disorders with systemic involvement. IL-17A/F is a proinflammatory cytokine involved in various neutrophilic inflammatory disorders. Here we show that IL-17A/F is highly expressed by...

  • Immunology: Targeting IL-17 in psoriasis. López, Juan Carlos // Nature Medicine;May2012, Vol. 18 Issue 5, p671 

    The article reports on clinical trials by Kim Papp and colleagues and Craig Leonardi and colleagues which reveal that interleukin -17 (IL-17) and its receptor are viable targets for the treatment of psoriasis.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics